Related Experiment Video
Updated: Mar 9, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
Pharmacology of testosterone replacement therapy preparations
Jennifer J Shoskes1, Meghan K Wilson2, Michael L Spinner2
1School of Pharmacy, Northeastern University, Boston, MA, 02115, USA.
Abstract:
The goal of testosterone replacement therapy (TRT) is to return serum testosterone levels to within physiologic range and improve symptoms in hypogonadal men. Some of the symptoms aimed to improve upon include decreased libido, erectile dysfunction, infertility, hot flashes, depressed mood, and loss of muscle mass or hair. Clinical use of testosterone for replacement therapy began approximately 70 years ago. Over the decades, numerous preparations and formulations have been developed primarily focusing on different routes of delivery and thus pharmacokinetics (PKs). Currently the routes of delivery approved for use by the United States Food and Drug Administration encompasses buccal, nasal, subdermal, transdermal, and intramuscular (IM). Many factors must be considered when a clinician is choosing the most correct formulation for a patient. As this decision depends highly on the patient, active patient participation is important for effective selection. The aim of this review is to describe and compare all testosterone preparations currently available and approved by the United States Food and Drug Administration. Areas of focus will include pharmacology, PKs, adverse effects, and specifics related to individual delivery routes.
Related Concept Videos
Testosterone: Functions and Regulation
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Bioequivalence: Overview
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

